Neurosteroids and GABAergic signaling in health and disease

Biomolecular Concepts

Volumn 4, Issue 1, 2013, Pages 29-42

  MacKenzie, Georgina ^a   Maguire, Jamie ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aminobutyric acid (GABA); Allopregnanolone; Allotetrahydrodeoxycorticosterone (THDOC); Neurosteroids

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANIMAL; BIOSYNTHESIS; CHEMISTRY; DISEASES; HEALTH; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE; GAMMA-AMINOBUTYRIC ACID; HEALTH; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, GABA-A; SIGNAL TRANSDUCTION;

EID: 84876515858     PISSN: 18685021     EISSN: 1868503X     Source Type: Journal    
DOI: 10.1515/bmc-2012-0033     Document Type: Review

References (189)

1. Baulieu EE, Robel P. Neurosteroids: a new brain function ? J Steroid Biochem Mol Biol 1990; 37: 395-403.
2. Compagnone NA, Mellon SH. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol 2000; 21: 1-56.
3. Reddy DS, Jian K. The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABAA receptors. J Pharmacol Exp Ther 2010; 334: 1031-41.
4. Belelli D, Harrison NL, Maguire J, Macdonald RL, Walker MC, Cope DW. Extrasynaptic GABAA receptors: form, pharmacology, and function. J Neurosci 2009; 29: 12757-63.
5. Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 2005; 6: 565-75.
6. Harrison NL, Simmonds MA. Alphaxalone selectively potentiates responses to GABA and muscimol in rat cuneate nucleus in vitro. J Physiol (Lond) 1984; 346: 42.
7. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid-hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986; 232: 1004-7.
8. Smith SS, Shen H, Gong QH, Zhou X. Neurosteroid regulation of GABA(A) receptors: focus on the alpha4 and delta subunits. Pharmacol Ther 2007; 116: 58-76.
9. Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res 2010; 186: 113-37.
10. Maguire J, Ferando I, Simonsen C, Mody I. Excitability changes related to GABAA receptor plasticity during pregnancy. J Neurosci 2009; 29: 9592-601.
11. Maguire J, Mody I. Neurosteroid synthesis-mediated regulation of GABA(A) receptors: relevance to the ovarian cycle and stress. J Neurosci 2007; 27: 2155-62.
12. Erskine MS. Effects of an anti-androgen and 5 alpha-reductase inhibitors on estrus duration in the cycling female rat. Physiol Behav 1983; 30: 519-24.
13. McCarthy MM, Felzenberg E, Robbins A, Pfaff DW, Schwartz- Giblin S. Infusions of diazepam and allopregnanolone into the midbrain central gray facilitate open-field behavior and sexual receptivity in female rats. Horm Behav 1995; 29: 279-95.
14. Frye CA. Novel substrates for, and sources of, progestogens for reproduction. J Neuroendocrinol 2011; 23: 961-73.
15. van BF, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology (Berl) 2003; 165: 97-110.
16. Akk G, Covey DF, Evers AS, Steinbach JH, Zorumski CF, Mennerick S. The influence of the membrane on neurosteroid actions at GABA(A) receptors. Psychoneuroendocrinology 2009; 34(Suppl 1): S59- 66.
17. Mellon SH, Griffin LD, Compagnone NA. Biosynthesis and action of neurosteroids. Brain Res Brain Res Rev 2001; 37: 3-12.
18. Mensah-Nyagan AG, Do-Rego JL, Beaujean D, Luu-The V, Pelletier G, Vaudry H. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol Rev 1999; 51: 63-81.
19. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-9.
20. Stromstedt M, Waterman MR. Messenger RNAs encoding steroidogenic enzymes are expressed in rodent brain. Brain Res Mol Brain Res 1995; 34: 75-88.
21. Mellon SH, Griffin LD. Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab 2002; 13: 35-43.
22. Agís-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, Guidotti A. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc Natl Acad Sci USA 2006; 103: 14602-7.
23. Purdy RH, Morrow AL, Moore PH, Paul SM. Stress-induced elevations of gamma-aminobutyric-acid type-A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991; 88: 4553-7.
24. Veliskova J, Desantis KA. Sex and hormonal influences on seizures and epilepsy. Horm Behav 2012.
25. Compagnone NA, Bulfone A, Rubenstein JL, Mellon SH. Steroidogenic enzyme P450c17 is expressed in the embryonic central nervous system. Endocrinology 1995; 136: 5212-23.
26. Reddy DS, Rogawski MA. Stress-induced deoxycorticosteronederived neurosteroids modulate GABA(A) receptor function and seizure susceptibility. J Neurosci 2002; 22: 3795-805.
27. Reddy DS. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions ? Trends Pharmacol Sci 2003; 24: 103-6.
28. Tuveri A, Paoletti AM, Orrù M, Melis GB, Marotto MF, Zedda P, Marrosu F, Sogliano C, Marra C, Biggio G, Concas A. Reduced serum level of THDOC, an anticonvulsant steroid, in women with perimenstrual catamenial epilepsy. Epilepsia 2008; 49: 1221-9.
29. Eser D, di Michele F, Zwanzger P, Pasini A, Baghai TC, Schüle C, Rupprecht R, Romeo E. Panic induction with cholecystokinin tetrapeptide (CCK-4) increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers. Neuropsychopharmacology 2005; 30: 192-5.
30. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci 2009; 10: 397-409.
31. Barbaccia ML, Roscetti G, Bolacchi F, Concas A, Mostallino MC, Purdy RH, Biggio G. Stress-induced increase in brain neuroactive steroids: antagonism by abecarnil. Pharmacol Biochem Behav 1996; 54: 205-10.
32. Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti A, Nappi RE, Luisi S, Palumbo M, Purdy RH, Luisi M. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab 1998; 83: 2099-103.
33. Gilbert Evans SE, Ross LE, Sellers EM, Purdy RH, Romach MK. 3alpha-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. Gynecol Endocrinol 2005; 21: 268-79.
34. Purdy RH, Moore PH, Morrow AL, Paul SM. Neurosteroids and GABA(A) receptor function. Adv Biochem Psychopharmacol 1992; 47: 87-92.
35. Concas A, Mostallino MC, Porcu P, Follesa P, Barbaccia ML, Trabucchi M, Purdy RH, Grisenti P, Biggio G. Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc Natl Acad Sci USA 1998; 95: 13284-9.
36. Vallee M, Rivera JD, Koob GF, Purdy RH, Fitzgerald RL. Quantification of neurosteroids in rat plasma and brain following swim stress and allopregnanolone administration using negative chemical ionization gas chromatography/mass spectrometry. Anal Biochem 2000; 287: 153-66.
37. Paul SM, Purdy RH. Neuroactive Steroids. FASEB J 1992; 6: 2311-22.
38. Reddy DS. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res 2009; 85: 1-30.
39. Pearson Murphy BE, Steinberg SI, Hu FY, Allison CM. Neuroactive ring A-reduced metabolites of progesterone in human plasma during pregnancy: elevated levels of 5 alphadihydroprogesterone in depressed patients during the latter half of pregnancy. J Clin Endocrinol Metab 2001; 86: 5981-7.
40. Luisi S, Petraglia F, Benedetto C, Nappi RE, Bernardi F, Fadalti M, Reis FM, Luisi M, Genazzani AR. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab 2000; 85: 2429-33.
41. Hill M, Cibula D, Havlíková H, Kancheva L, Fait T, Kancheva R, Parízek A, Stárka L. Circulating levels of pregnanolone isomers during the third trimester of human pregnancy. J Steroid Biochem Mol Biol 2007; 105: 166-75.
42. Liu S, Sjovall J, Griffiths WJ. Neurosteroids in rat brain: extraction, isolation, and analysis by nanoscale liquid chromatography- electrospray mass spectrometry. Anal Chem 2003; 75: 5835-46.
43. Liere P, Pianos A, Eychenne B, Cambourg A, Liu S, Griffiths W, Schumacher M, Sjövall J, Baulieu EE. Novel lipoidal derivatives of pregnenolone and dehydroepiandrosterone and absence of their sulfated counterparts in rodent brain. J Lipid Res 2004; 45: 2287-302.
44. Bixo M, Andersson A, Winblad B, Purdy RH, Backstrom T. Progesterone, 5 alpha-pregnane-3,20-dione and 3 alphahydroxy- 5 alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 1997; 764: 173-8.
45. Kancheva R, Hill M, Novak Z, Chrastina J, Kancheva L, Starka L. Neuroactive steroids in periphery and cerebrospinal fluid. Neuroscience 2011; 191: 22-7.
46. Lacroix C, Fiet J, Benais JP, Gueux B, Bonete R, Villette JM, Gourmel B, Dreux C. Simultaneous radioimmunoassay of progesterone, androst-4-enedione, pregnenolone, dehydroepiandrosterone and 17-hydroxyprogesterone in specific regions of human brain. J Steroid Biochem 1987; 28: 317-25.
47. Higashi T, Daifu Y, Ikeshima T, Yagi T, Shimada K. Studies on neurosteroids XV. Development of enzyme-linked immunosorbent assay for examining whether pregnenolone sulfate is a veritable neurosteroid. J Pharm Biomed Anal 2003; 30: 1907-17.
48. Henderson LP. Steroid modulation of GABAA receptor-mediated transmission in the hypothalamus: effects on reproductive function. Neuropharmacology 2007; 52: 1439-53.
49. Schumacher M, Liere P, Akwa Y, Rajkowski K, Griffiths W, Bodin K, Sjövall J, Baulieu EE. Pregnenolone sulfate in the brain: a controversial neurosteroid. Neurochem Int 2008; 52: 522-40.
50. Simon J, Wakimoto H, Fujita N, Lalande M, Barnard EA. Analysis of the set of GABA(A) receptor genes in the human genome. J Biol Chem 2004; 279: 41422-35.
51. Chang Y, Wang R, Barot S, Weiss DS. Stoichiometry of a recombinant GABAA receptor. J Neurosci 1996; 16: 5415-24.
52. Tretter V, Ehya N, Fuchs K, Sieghart W. Stoichiometry and assembly of a recombinant GABAA receptor subtype. J Neurosci 1997; 17: 2728-37.
53. Mody I, Pearce RA. Diversity of inhibitory neurotransmission through GABA A receptors. Trends Neurosci 2004; 27: 569-75.
54. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 2005; 6: 215-29.
55. Nusser Z, Sieghart W, Somogyi P. Segregation of different GABA(A) receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. J Neurosci 1998; 18: 1693-703.
56. Wei WZ, Zhang NH, Peng ZC, Houser CR, Mody I. Perisynaptic localization of delta subunit-containing GABA(A) receptors and their activation by GABA spillover in the mouse dentate gyrus. J Neurosci 2003; 23: 10650-61.
57. Saxena NC, Macdonald RL. Properties of putative cerebellar gamma-aminobutyric acid(A) receptor isoforms. Mol Pharmacol 1996; 49: 567-79.
58. Brickley SG, CullCandy SG, Farrant M. Development of a tonic form of synaptic inhibition in rat cerebellar granule cells resulting from persistent activation of GABA(A) receptors. J Physiol Lond 1996; 497: 753-9.
59. Wu Y, Wang W, Diez-Sampedro A, Richerson GB. Nonvesicular inhibitory neurotransmission via reversal of the GABA transporter GAT-1. Neuron 2007; 56: 851-65.
60. Lambert JJ, Belelli D, HillVenning C, Peters JA. Neurosteroids and GABA(A) receptor function. Trends Pharmacol Sci 1995; 16: 295-303.
61. Lambert JJ, Belelli D, Harney SC, Peters JA, Frenguelli BG. Modulation of native and recombinant GABA(A) receptors by endogenous and synthetic neuroactive steroids. Brain Res Rev 2001; 37: 68-80.
62. Belelli D, Casula A, Ling A, Lambert JJ. The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors. Neuropharmacology 2002; 43: 651-61.
63. Hosie AM, Wilkins ME, da Silva HM, Smart TG. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 2006; 444: 486-9.
64. Stell BM, Brickley SG, Tang CY, Farrant M, Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABA(A) receptors. Proc Natl Acad Sci USA 2003; 100: 14439-44.
65. Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, Lagenaur C, Tretter V, Sieghart W, Anagnostaras SG, Sage JR, Fanselow MS, Guidotti A, Spigelman I, Li Z, DeLorey TM, Olsen RW, Homanics GE. Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci USA 1999; 96: 12905-10.
66. Houston CM, McGee TP, Mackenzie G, Troyano-Cuturi K, Rodriguez PM, Kutsarova E, Diamanti E, Hosie AM, Franks NP, Brickley SG. Are extrasynaptic GABAA receptors important targets for sedative/hypnotic drugs ? J Neurosci 2012; 32: 3887-97.
67. Wohlfarth KM, Bianchi MT, Macdonald RL. Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit. J Neurosci 2002; 22: 1541-9.
68. Bianchi MT, Macdonald RL. Neurosteroids shift partial agonist activation of GABA(A) receptor channels from low- to high-efficacy gating patterns. J Neurosci 2003; 23: 10934-43.
69. Brickley SG, Mody I. Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. Neuron 2012; 73: 23-34.
70. Twyman RE, Macdonald RL. Neurosteroid regulation of GABAA receptor single-channel kinetic properties of mouse spinal cord neurons in culture. J Physiol 1992; 456: 215-45.
71. Chisari M, Eisenman LN, Covey DF, Mennerick S, Zorumski CF. The sticky issue of neurosteroids and GABA(A) receptors. Trends Neurosci 2010; 33: 299-306.
72. Hosie AM, Clarke L, da SH, Smart TG. Conserved site for neurosteroid modulation of GABA A receptors. Neuropharmacology 2009; 56: 149-54.
73. Hosie AM, Wilkins ME, Smart TG. Neurosteroid binding sites on GABA(A) receptors. Pharmacol Ther 2007; 116: 7-19.
74. Mitchell EA, Herd MB, Gunn BG, Lambert JJ, Belelli D. Neurosteroid modulation of GABAA receptors: molecular determinants and significance in health and disease. Neurochem Int 2008; 52: 588-95.
75. Akk G, Li P, Bracamontes J, Reichert DE, Covey DF, Steinbach JH. Mutations of the GABA-A receptor alpha1 subunit M1 domain reveal unexpected complexity for modulation by neuroactive steroids. Mol Pharmacol 2008; 74: 614-27.
76. Bracamontes JR, Li P, Akk G, Steinbach JH. A neurosteroid potentiation site can be moved among GABAA receptor subunits. J Physiol 2012. doi: 10.1113/jphysiol.2012.237255.
77. Chen ZW, Manion B, Townsend RR, Reichert DE, Covey DF, Steinbach JH, Sieghart W, Fuchs K, Evers AS. Neurosteroid analogue photolabeling of a site in the TM3 domain of the beta3 subunit of the GABAA receptor. Mol Pharmacol 2012; 82: 408-19.
78. Li GD, Chiara DC, Cohen JB, Olsen RW. Neurosteroids allosterically modulate binding of the anesthetic etomidate to gamma-aminobutyric acid type A receptors. J Biol Chem 2009; 284: 11771-5.
79. Davies PA, Hanna MC, Hales TG, Kirkness EF. Insensitivity to anaesthetic agents conferred by a class of GABA(A) receptor subunit. Nature 1997; 385: 820-3.
80. Ranna M, Sinkkonen ST, Moykkynen T, Uusi-Oukari M, Korpi ER. Impact of epsilon and theta subunits on pharmacological properties of alpha3beta1 GABAA receptors expressed in Xenopus oocytes. BMC Pharmacol 2006; 6: 1.
81. Whiting PJ, McAllister G, Vassilatis D, Bonnert TP, Heavens RP, Smith DW, Hewson L, O ' Donnell R, Rigby MR, Sirinathsinghji DJ, Marshall G, Thompson SA, Wafford KA, Vasilatis D. Neuronally restricted RNA splicing regulates the expression of a novel GABAA receptor subunit conferring atypical functional properties [corrected; erratum to be published]. J Neurosci 1997; 17: 5027-37.
82. Thompson SA, Bonnert TP, Whiting PJ, Wafford KA. Functional characteristics of recombinant human GABA(A) receptors containing the epsilon-subunit. Toxicol Lett 1998; 100 - 1: 233-8.
83. Thompson SA, Bonnert TP, Cagetti E, Whiting PJ, Wafford KA. Overexpression of the GABA(A) receptor epsilon subunit results in insensitivity to anaesthetics. Neuropharmacology 2002; 43: 662-8.
84. Maksay G, Thompson SA, Wafford KA. The pharmacology of spontaneously open alpha 1 beta 3 epsilon GABA A receptorionophores. Neuropharmacology 2003; 44: 994-1002.
85. Wagner DA, Goldschen-Ohm MP, Hales TG, Jones MV. Kinetics and spontaneous open probability conferred by the epsilon subunit of the GABA A receptor. J Neurosci 2005; 25: 10462-8.
86. Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA. Neurosteroid modulation of GABA(A) receptors. Prog Neurobiol 2003; 71: 67-80.
87. Hengen KB, Nelson NR, Stang KM, Johnson SM, Crader SM, Watters JJ, Mitchell GS, Behan M. Increased GABA(A) receptor epsilon-subunit expression on ventral respiratory column neurons protects breathing during pregnancy. PLoS One 2012; 7: e30608.
88. Semyanov A, Walker MC, Kullmann DM, Silver RA. Tonically active GABA(A) receptors: modulating gain and maintaining the tone. Trends Neurosci 2004; 27: 262-9.
89. Silver RA. Neuronal arithmetic. Nat Rev Neurosci 2010; 11: 474-89.
90. Pavlov I, Savtchenko LP, Kullmann DM, Semyanov A, Walker MC. Outwardly rectifying tonically active GABAA receptors in pyramidal cells modulate neuronal offset, not gain. J Neurosci 2009; 29: 15341-50.
91. Maguire J, Mody I. Steroid hormone fluctuations and GABA(A)R plasticity. Psychoneuroendocrinology 2009; 34: S84 - 90.
92. Follesa P, Biggio F, Caria S, Gorini G, Biggio G. Modulation of GABA(A) receptor gene expression by allopregnanolone and ethanol. Eur J Pharmacol 2004; 500: 413-25.
93. Majewska MD, Fordrice F, Falkay G. Pregnancy-induced alterations of GABAA receptor sensitivity in maternal brain - an antecedent of post-partum blues. Brain Res 1989; 482: 397-401.
94. Maguire J, Mody I. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron 2008; 59: 207-13.
95. Maguire JL, Stell BM, Rafizadeh M, Mody I. Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 2005; 8: 797-804.
96. Smith SS, Gong QH, Li XS, Moran MH, Bitran D, Frye CA, Hsu FC. Withdrawal from 3 alpha-OH-5 alpha-pregnan- 20-one using a pseudopregnancy model alters the kinetics of hippocampal GABA(A)-gated current and increases the GABA(A), receptor alpha 4 subunit in association with increased anxiety. J Neurosci 1998; 18: 5275-84.
97. Shen H, Gong QH, Yuan M, Smith SS. Short-term steroid treatment increases delta GABA(A) receptor subunit expression in rat CA1 hippocampus: pharmacological and behavioral effects. Neuropharmacology 2005 ; 49: 573-86.
98. Griffiths JL, Lovick TA. GABAergic neurones in the rat periaqueductal grey matter express alpha4, beta1 and delta GABAA receptor subunits: plasticity of expression during the estrous cycle. Neuroscience 2005; 136: 457-66.
99. Penatti CA, Oberlander JG, Davis MC, Porter DM, Henderson LP. Chronic exposure to anabolic androgenic steroids alters activity and synaptic function in neuroendocrine control regions of the female mouse. Neuropharmacology 2011; 61: 653-64.
100. Concas A, Follesa P, Barbaccia ML, Purdy RH, Biggio G. Physiological modulation of GABA(A) receptor plasticity by progesterone metabolites. Eur J Pharmacol 1999; 375: 225-35.
101. Follesa P, Floris S, Tuligi G, Mostallino MC, Concas A, Biggio G. Molecular and functional adaptation of the GABA(A) receptor complex during pregnancy and after delivery in the rat brain. Eur J Neurosci 1998; 10: 2905-12.
102. Gulinello M, Gong QH, Li X, Smith SS. Short-term exposure to a neuroactive steroid increases alpha 4 GABA(A) receptor subunit levels in association with increased anxiety in the famale rat. Brain Res 2001; 910: 55-66.
103. Hsu FC, Waldeck R, Faber DS, Smith SS. Neurosteroid effects on GABAergic synaptic plasticity in hippocampus. J Neurophysiol 2003; 89: 1929-40.
104. di Michele F, Longone P, Romeo E, Lucchetti S, Brusa L, Pierantozzi M, Bassi A, Bernardi G, Stanzione P. Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson ' s disease. Neurol Sci 2003; 24: 172-3.
105. Guidotti A, Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability ? Biol Psychiatry 1998; 44: 865-73.
106. Romeo E, Ströhle A, Spalletta G, di Michele F, Hermann B, Holsboer F, Pasini A, Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998; 155: 910-3.
107. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998; 95: 3239-44.
108. Schumacher M, Weill-Engerer S, Liere P, Robert F, Franklin RJ, Garcia-Segura LM, Lambert JJ, Mayo W, Melcangi RC, Parducz A, Suter U, Carelli C, Baulieu EE, Akwa Y. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog Neurobiol 2003; 71: 3-29.
109. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003; 60: 133-41.
110. Brambilla F, Biggio G, Pisu MG, Purdy RH, Gerra G, Zaimovich A, Serra M. Plasma concentrations of anxiolytic neurosteroids in men with normal anxiety scores: a correlation analysis. Neuropsychobiology 2004; 50: 6-9.
111. Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC, Ervin JF, Butterfield MI, Blazer DG, Massing MW, Lieberman JA. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer ' s disease. Biol Psychiatry 2006; 60: 1287-94.
112. van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology (Berl) 2003; 165: 97-110.
113. Pinna G, Costa E, Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol 2009; 9: 24-30.
114. Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl) 2006; 186: 362-72.
115. Khisti RT, Chopde CT. Serotonergic agents modulate antidepressant-like effect of the neurosteroid 3alpha-hydroxy- 5alpha-pregnan-20-one in mice. Brain Res 2000; 865: 291-300.
116. Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 2000; 67: 137-43.
117. Girdler SS, Straneva PA, Light KC, Pedersen CA, Morrow AL. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 2001; 49: 788-97.
118. Wihlback AC, Sundstrom-Poromaa I, Backstrom T. Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders. Psychopharmacology (Berl) 2006; 186: 388-401.
119. Freeman EW, Frye CA, Rickels K, Martin PA, Smith SS. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J Clin Psychopharmacol 2002; 22: 516-20.
120. Bäckström T, Andreen L, Birzniece V, Björn I, Johansson IM, Nordenstam-Haghjo M, Nyberg S, Sundström-Poromaa I, Wahlström G, Wang M, Zhu D. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 2003; 17: 325-42.
121. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28: 1-23.
122. Rasmusson AM, Pinna G, Paliwal P, Weisman D, Gottschalk C, Charney D, Krystal J, Guidotti A. Decreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorder. Biol Psychiatry 2006; 60: 704-13.
123. Ströhle A, Romeo E, di Michele F, Pasini A, Yassouridis A, Holsboer F, Rupprecht R. GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am J Psychiatry 2002; 159: 145-7.
124. Ströhle A, Romeo E, di Michele F, Pasini A, Yassouridis A, Holsboer F, Rupprecht R. Induced panic attacks shift gammaaminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 2003; 60: 161-8.
125. Zwanzger P, Eser D, Padberg F, Baghai TC, Schüle C, Rupprecht R, di Michele F, Romeo E, Pasini A, Ströhle A. Neuroactive steroids are not affected by panic induction with 50 microg cholecystokinin-tetrapeptide (CCK-4) in healthy volunteers. J Psychiatr Res 2004; 38: 215-7.
126. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 2003; 28: 139-68.
127. Crawley JN, Glowa JR, Majewska MD, Paul SM. Anxiolytic activity of an endogenous adrenal steroid. Brain Res 1986; 398: 382-5.
128. Bitran D, Shiekh M, Mcleod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABA(A) receptors. J Neuroendocrinol 1995; 7: 171-7.
129. Weiland NG, Orchinik M. Specific subunit mRNAs of the GABAA receptor are regulated by progesterone in subfields of the hippocampus. Brain Res Mol Brain Res 1995; 32: 271-8.
130. Reddy DS, Kulkarni SK. Development of neurosteroid-based novel psychotropic drugs. Prog Med Chem 2000; 37: 135-75.
131. Finn DA, Roberts AJ, Long S, Tanchuck M, Phillips TJ. Neurosteroid consumption has anxiolytic effects in mice. Pharmacol Biochem Behav 2003; 76: 451-62.
132. Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3A-hydroxy-5A[beta]-pregnan-20-one - endogenous metabolites of progesterone that are active at the GABA-A receptor. Brain Res 1991; 561: 157-61.
133. Reddy DS, Kulkarni SK. Differential anxiolytic effects of neurosteroids in the mirrored chamber behavior test in mice. Brain Res 1997; 752: 61-71.
134. Rodgers RJ, Johnson NJ. Behaviorally selective effects of neuroactive steroids on plus-maze anxiety in mice. Pharmacol Biochem Behav 1998; 59: 221-32.
135. Sarkar J, Wakefield S, Mackenzie G, Moss SJ, Maguire J. Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors. J Neurosci 2011; 31: 18198-210.
136. Biagini G, Baldelli E, Longo D, Pradelli L, Zini I, Rogawski MA, Avoli M. Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. Exp Neurol 2006; 201: 519-24.
137. Biagini G, Longo D, Baldelli E, Zoli M, Rogawski MA, Bertazzoni G, Avoli M. Neurosteroids and epileptogenesis in the pilocarpine model: evidence for a relationship between P450scc induction and length of the latent period. Epilepsia 2009; 50(Suppl 1): 53-8.
138. Frye CA. The neurosteroid 3 alpha, 5 alpha-THP has antiseizure and possible neuroprotective effects in an animal model of epilepsy. Brain Res 1995; 696: 113-20.
139. Peng ZC, Huang CS, Stell BM, Mody I, Houser CR. Altered expression of the delta subunit of the GABA(A) receptor in a mouse model of temporal lobe epilepsy. J Neurosci 2004; 24: 8629-39.
140. Reddy DS, Rogawski MA. Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model. Epilepsy Res 2010; 89: 254-60.
141. Reddy DS, Rogawski MA. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J Pharmacol Exp Ther 2000; 295: 1241-8.
142. Lawrence C, Martin BS, Sun C, Williamson J, Kapur J. Endogenous neurosteroid synthesis modulates seizure frequency. Ann Neurol 2010; 67: 689-93.
143. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997; 38: 1082-8.
144. Herzog AG. Progesterone Therapy in Women with Complex Partial and Secondary Generalized Seizures. Neurology 1995; 45: 1660-2.
145. Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology 1999; 52: 1917 - 8.
146. Herzog AG, Frye CA. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 2003; 53: 390-1.
147. Moran MH, Smith SS. Progesterone withdrawal I: pro-convulsant effects. Brain Res 1998; 807: 84-90.
148. Reddy DS, Kim HY, Rogawski MA. Neurosteroid withdrawal model of perimenstrual catamenial epilepsy. Epilepsia 2001; 42: 328-36.
149. Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J Pharmacol Exp Ther 2000; 294: 909-15.
150. Gulinello M, Gong QH, Smith SS. Progesterone withdrawal increases the alpha 4 subunit of the GABA(A) receptor in male rats in association with anxiety and altered pharmacology - a comparison with female rats. Neuropharmacology 2002; 43: 701-14.
151. Allan AM, Harris RA. Gamma-aminobutyric acid and alcohol actions: neurochemical studies of long sleep and short sleep mice. Life Sci 1986; 39: 2005-15.
152. Suzdak PD, Schwartz RD, Skolnick P, Paul SM. Ethanol stimulates gamma-aminobutyric acid receptor-mediated chloride transport in rat brain synaptoneurosomes. Proc Natl Acad Sci USA 1986; 83: 4071-5.
153. Helms CM, Rossi DJ, Grant KA. Neurosteroid influences on sensitivity to ethanol. Front Endocrinol (Lausanne) 2012; 3: 10.
154. Wei WZ, Faria LC, Mody I. Low ethanol concentrations selectively augment the tonic inhibition mediated by delta subunit-containing GABA(A) receptors in hippocampal neurons. J Neurosci 2004; 24: 8379-82.
155. Hanchar HJ, Dodson PD, Olsen RW, Otis TS, Wallner M. Alcoholinduced motor impairment caused by increased extrasynaptic GABA(A) receptor activity. Nat Neurosci 2005; 8: 339-45.
156. Glykys J, Mody I. Activation of GABAA receptors: views from outside the synaptic cleft. Neuron 2007; 56: 763-70.
157. Hanchar HJ, Wallner M, Olsen RW. Alcohol effects on gammaaminobutyric acid type A receptors: are extrasynaptic receptors the answer ? Life Sci 2004; 76: 1-8.
158. Olsen RW, Hanchar HJ, Meera P, Wallner M. GABAA receptor subtypes: the " one glass of wine " receptors. Alcohol 2007; 41: 201-9.
159. Mody I. Extrasynaptic GABAA receptors in the crosshairs of hormones and ethanol. Neurochem Int 2008; 52: 60-4.
160. Borghese CM, Harris RA. Studies of ethanol actions on recombinant delta-containing gamma-aminobutyric acid type A receptors yield contradictory results. Alcohol 2007; 41: 155-62.
161. Botta P, Radcliffe RA, Carta M, Mameli M, Daly E, Floyd KL, Deitrich RA, Valenzuela CF. Modulation of GABAA receptors in cerebellar granule neurons by ethanol: a review of genetic and electrophysiological studies. Alcohol 2007; 41: 187-99.
162. Morrow AL, VanDoren MJ, Devaud LL. Effects of progesterone or neuroactive steroid ? Nature 1998; 395: 652-3.
163. Barbaccia ML, Affricano D, Trabucchi M, Purdy RH, Colombo G, Agabio R, Gessa GL. Ethanol markedly increases " GABAergic " neurosteroids in alcohol-preferring rats. Eur J Pharmacol 1999; 384: R1 - 2.
164. Morrow AL, Janis GC, VanDoren MJ, Matthews DB, Samson HH, Janak PH, Grant KA. Neurosteroids mediate pharmacological effects of ethanol: a new mechanism of ethanol action ? Alcohol Clin Exp Res 1999; 23: 1933-40.
165. VanDoren MJ, Matthews DB, Janis GC, Grobin AC, Devaud LL, Morrow AL. Neuroactive steroid 3alpha-hydroxy-5alphapregnan- 20-one modulates electrophysiological and behavioral actions of ethanol. J Neurosci 2000; 20: 1982 - 9.
166. O ' Dell LE, Alomary AA, Vallee M, Koob GF, Fitzgerald RL, Purdy RH. Ethanol-induced increases in neuroactive steroids in the rat brain and plasma are absent in adrenalectomized and gonadectomized rats. Eur J Pharmacol 2004; 484: 241-7.
167. Morrow AL, Porcu P, Boyd KN, Grant KA. Hypothalamicpituitary- adrenal axis modulation of GABAergic neuroactive steroids influences ethanol sensitivity and drinking behavior. Dialogues Clin Neurosci 2006; 8: 463-77.
168. Biggio G, Concas A, Follesa P, Sanna E, Serra M. Stress, ethanol, and neuroactive steroids. Pharmacol Ther 2007; 116: 140-71.
169. Morrow AL, Biggio G, Serra M, Becker HC, Lopez MF, Porcu P, Alward SE, O ' Buckley TK. The role of neuroactive steroids in ethanol/stress interactions: proceedings of symposium VII at the Volterra conference on alcohol and stress, May 2008. Alcohol 2009; 43: 521-30.
170. Khisti RT, VanDoren MJ, O'Buckley T, Morrow AL. Neuroactive steroid 3 alpha-hydroxy-5 alpha-pregnan-20-one modulates ethanol-induced loss of righting reflex in rats. Brain Res 2003; 980: 255-65.
171. Matthews DB, Morrow AL, Tokunaga S, McDaniel JR. Acute ethanol administration and acute allopregnanolone administration impair spatial memory in the Morris water task. Alcohol Clin Exp Res 2002; 26: 1747-51.
172. Morrow AL, VanDoren MJ, Penland SN, Matthews DB. The role of GABAergic neuroactive steroids in ethanol action, tolerance and dependence. Brain Res Brain Res Rev 2001; 37: 98-109.
173. Hirani K, Khisti RT, Chopde CT. Behavioral action of ethanol in Porsolt ' s forced swim test: modulation by 3 alpha-hydroxy-5 alpha-pregnan-20-one. Neuropharmacology 2002; 43: 1339-50.
174. Hirani K, Sharma AN, Jain NS, Ugale RR, Chopde CT. Evaluation of GABAergic neuroactive steroid 3alpha-hydroxy-5alphapregnane- 20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats. Psychopharmacology (Berl) 2005; 180: 267-78.
175. Khisti RT, VanDoren MJ, Matthews DB, Morrow AL. Ethanolinduced elevation of 3 alpha-hydroxy-5 alpha-pregnan-20-one does not modulate motor incoordination in rats. Alcohol Clin Exp Res 2004; 28: 1249-56.
176. Luchetti S, Huitinga I, Swaab DF. Neurosteroid and GABA-A receptor alterations in Alzheimer ' s disease, Parkinson ' s disease and multiple sclerosis. Neuroscience 2011; 191: 6-21.
177. Mellon SH. Neurosteroid regulation of central nervous system development. Pharmacol Ther 2007; 116: 107-24.
178. Mackenzie SM, Dewar D, Stewart W, Fraser R, Connell JM, Davies E. The transcription of steroidogenic genes in the human cerebellum and hippocampus: a comparative survey of normal and Alzheimer ' s tissue. J Endocrinol 2008; 196: 123-30.
179. Wojtal K, Trojnar MK, Czuczwar SJ. Endogenous neuroprotective factors: neurosteroids. Pharmacol Rep 2006; 58: 335-40.
180. Griffin LD, Gong W, Verot L, Mellon SH. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 2004; 10: 704-11.
181. Liao G, Cheung S, Galeano J, Ji AX, Qin Q, Bi X. Allopregnanolone treatment delays cholesterol accumulation and reduces autophagic/lysosomal dysfunction and inflammation in Npc1-/- mouse brain. Brain Res 2009; 1270: 140-51.
182. Mellon SH, Gong W, Schonemann MD. Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res Rev 2008; 57: 410-20.
183. Rupprecht R, Reul JM, Trapp T, van Steensel B, Wetzel C, Damm K, Zieglgänsberger W, Holsboer F. Progesterone receptormediated effects of neuroactive steroids. Neuron 1993; 11: 523-30.
184. Nohria V, Giller E. Ganaxolone. Neurotherapeutics 2007; 4: 102-5.
185. Reddy DS, Woodward R. Ganaxolone: a prospective overview. Drugs Future 2004; 29: 227-42.
186. Kerrigan JF, Shields WD, Nelson TY, Bluestone DL, Dodson WE, Bourgeois BF, Pellock JM, Morton LD, Monaghan EP. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res 2000; 42: 133-9.
187. Beekman M, Ungard JT, Gasior M, Carter RB, Dijkstra D, Goldberg SR, Witkin JM. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. J Pharmacol Exp Ther 1998; 284: 868-77.
188. Gasior M, Ungard JT, Beekman M, Carter RB, Witkin JM. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology 2000; 39: 1184-96.
189. Laxer K, Blum D, Abou-Khalil BW, Morrell MJ, Lee DA, Data JL, Monaghan EP. Assessment of ganaxolone ' s anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. Epilepsia 2000; 41: 1187-94.